VivoSim Labs, INC.
VIVS · XNASCIK 1497253fmd_1YD1NQ0GGTQZTS4TFA28M76CXWManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 67 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 4 | 5 | 3 | 2 | 0 | 2 | 0 | 0 | 0 | 0 |
| Cost of revenue | 1 | 1 | 1 | 0 | 0 | – | – | – | 0 | 0 |
| Gross profit | 3 | 4 | 3 | 2 | 0 | – | – | – | 0 | 0 |
| Research and development | 20 | 18 | 15 | 5 | 1 | 3 | 9 | 5 | 5 | 4 |
| Selling, general and administrative | 22 | 21 | 15 | 18 | 16 | 10 | 9 | 10 | 8 | 7 |
| Operating income | (39) | (35) | (27) | (21) | (17) | (11) | (18) | (15) | (13) | (11) |
| Interest expense | 0 | – | – | – | – | – | – | – | 0 | 0 |
| Interest and investment income | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | 0 | 1 | 3 | 0 | 0 | 0 | 0 | 10 | (2) |
| Income before taxes | – | – | – | – | – | – | – | – | (2) | (14) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | (2) | (14) |
| Net income | (38) | (35) | (27) | (19) | (17) | (11) | (17) | (15) | (2) | (14) |